Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;22(12):2209-2226.
doi: 10.1111/dom.14165. Epub 2020 Sep 6.

Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results

Kevin M Pantalone  1 , Kashif Munir  2 , Clinton M Hasenour  3 , Charles M Atisso  3 , Oralee J Varnado  3 , Juan M Maldonado  3 , Manige Konig  3
Affiliations
Review

Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results

Kevin M Pantalone et al. Diabetes Obes Metab. 2020 Dec.

Abstract

Despite treatment advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease (CVD) remains the leading cause of morbidity and mortality in people with diabetes. People with type 2 diabetes (T2D) have a 2- to 4-fold increased risk of CVD and CV death. Individuals with T2D have not seen the same improvements in CV morbidity and mortality as those without T2D. Given this, it is important to understand the CV impact of drugs used to treat T2D. In patients with T2D, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a reduction in HbA1c and body weight regardless of their differences in chemical structure and pharmacokinetic variables. Glycaemic efficacy, accompanied by the potential for weight reduction and a low risk of hypoglycaemia, has moved GLP-1 RAs to the first treatment of choice following metformin monotherapy in the latest American Diabetes Association treatment guidelines. Additionally, all GLP-1 RAs have shown CV safety and several have proven CV benefit. GLP-1 RAs have been evaluated in cardiovascular outcomes trials (CVOTs) of varying sizes, designs and patient populations with differing reported effects on CV outcomes. The purpose of this article is to review the completed GLP-1 RA CVOTs with special attention to how their design, size, patient populations and conduct may influence the interpretation of results.

Keywords: cardiovascular diseaseGLP-1type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

KMP and KM do not declare any interests. CMH is a former employee of Eli Lilly and Company. CMA, OJV, JMM and MK are employees of Eli Lilly and own stock in the company.

References

    1. American Heart Association. Cardiovascular Disease and Diabetes . https://www.heart.org/en/health-topics/diabetes/why-diabetes-matters/car.... Accessed August 16, 2019.
    1. Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care. 2004;27(12):2898‐2904. - PubMed
    1. Iglay K, Hannachi H, Joseph Howie P, et al. Prevalence and co‐prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243‐1252. - PubMed
    1. American Diabetes Association . Statistics about Diabetes. http://www.diabetes.org/diabetes-basics/statistics/. Accessed August 28, 2019.
    1. American Diabetes Association . Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917‐928. - PMC - PubMed

Publication types

MeSH terms

Substances